Search
Menu
Cognex Corp. - Smart Sensor 3-24 GIF LB

Spectranetics Concludes LARS Trial

Facebook X LinkedIn Email
COLORADO SPRINGS, Colo., Nov. 28 -- The Spectranetics Corp. said it is concluding its LARS (laser angioplasty for restenosed stents) clinical trial, in light of recent approval from the FDA to market its products to clear clogged coronary stents (thin steel mesh tubes used to support the walls of arteries) prior to radiation treatment.

The company will continue to follow all 138 LARS patients through the study's nine-month follow-up period. It said its clinical priorities for 2002 continue to be accelerating PELA and LACI clinical trials involving excimer laser energy to clear blockages in leg arteries.

Ohara Corp. - Optical Glass, Polish substrates 10-23

Published: November 2001
News & Features

We use cookies to improve user experience and analyze our website traffic as stated in our Privacy Policy. By using this website, you agree to the use of cookies unless you have disabled them.